All News

The SUCCESSOR-2 study shows MeziKd improves progression-free survival for relapsed multiple myeloma patients previously treated with anti-CD38 drugs.

Dr. Christopher Koller discusses rising kidney cancer diagnoses in younger adults, key risk factors and why early detection remains critical.

A personal look at choosing to be a caregiver, the challenges faced, and the lessons learned while supporting a sister through years with cancer.

Ipsen has pulled Tazverik from all markets after a trial found risks of secondary blood cancers, affecting patients with follicular lymphoma and epithelioid sarcoma.

Dr. Hope Rugo explains how antibody-drug conjugates like Datroway and Trodelvy are shifting the treatment landscape for patients with TNBC.

The FDA has received a new application for Anktiva plus BCG to treat BCG-unresponsive non–muscle invasive bladder cancer with papillary tumors.

FDA grants priority review to Enhertu for patients with HER2-positive early breast cancer and residual invasive disease after neoadjuvant treatment.

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

Zovegalisib plus Faslodex elicited responses in patients with HR-positive, HER2-negative, PIK3CA-mutant advanced breast cancer.

Manage your stage 3 ET diagnosis with this guide on high-risk treatments, side effects and new NCCN-preferred options to empower your next visit.

Here are five key takeaways regarding the use of GLP-1 receptor agonists in patients who are undergoing breast cancer treatment.

At the Miami Breast Cancer Conference, Dr. Heather A. Parsons shared growing evidence for the prognostic value of circulating tumor DNA.

A comprehensive guide to medullary thyroid cancer (MTC), covering symptoms, RET genetic testing, surgical options and advanced targeted therapies.

New data show that Enhertu had similar safety in the real world as in clinical trials in patients with HER2-low metastatic breast cancer.

A community study finds Enhertu effective for HER2-low mBC, with over half of patients seeing tumor shrinkage and high one-year survival rates.

New data show more women over 70 are safely skipping sentinel lymph node biopsies for HR+ breast cancer, reducing unnecessary surgery and risks.

After abnormal mammogram, family history and testing revealed a BRCA1 mutation, leading one woman to choose preventive surgeries and share her experience.

Resilience programs using mindfulness and cognitive behavioral strategies help cancer survivors manage their fear and stress, as well as adjust after treatment.

Dr. Eric Singer reveals the latest advances in kidney cancer care that help patients live longer and maintain quality of life.

Common myths about cervical cancer and HPV may discourage screening. Experts say vaccination helps but does not replace regular testing.

FDA approved Tecvayli plus Darzalex Faspro for relapsed or refractory multiple myeloma after prior therapy, based on trial results showing longer disease control.

Experts say resilience helps patients with cancer adjust emotionally and physically after treatment, easing fear of recurrence and supporting long-term recovery.

A stage 4 prostate cancer survivor shares his story of positivity and gratitude.

Phase 2 COMPASSION-03 data showed cadonilimab produced durable survival in patients with recurrent or metastatic cervical cancer after platinum chemotherapy.

Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy, discussed how the standard of care for melanoma is evolving.

FDA approvals, survival gains and equity research led February’s top gynecologic cancer stories, alongside a survivor Q&A on mental health.

Namodenoson was well tolerated in a phase 2a study of advanced pancreatic cancer, with one-third of patients alive at data cutoff.